82996
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- fusion
- YAP1_MAMLD1
- e1_e2
- E2
- umap1_2d
- -6.534264612
- umap2_2d
- 0.035573766
- umap1_3d
- -0.11748977
- umap2_3d
- 3.015205024
- umap3_3d
- 1.362178365
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- TNFA_SIGNALING_VIA_NFKB+0.400
- IL6_JAK_STAT3_SIGNALING+0.380
- MYOGENESIS+0.370
- COAGULATION+0.360
- HYPOXIA+0.360
- INFLAMMATORY_RESPONSE+0.330
- KRAS_SIGNALING_DN+0.310
- TGF_BETA_SIGNALING+0.270
- ALLOGRAFT_REJECTION+0.260
Top 10 suppressed
- PROTEIN_SECRETION-0.380
- G2M_CHECKPOINT-0.370
- E2F_TARGETS-0.360
- MITOTIC_SPINDLE-0.230
- SPERMATOGENESIS-0.230
- MTORC1_SIGNALING-0.210
- MYC_TARGETS_V1-0.200
- ANDROGEN_RESPONSE-0.180
- OXIDATIVE_PHOSPHORYLATION-0.160
- PI3K_AKT_MTOR_SIGNALING-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_J8VX4D17 | EPN | Posterior Fossa EPN | 0.904 |
| 2 | BS_J8VX4D17 | Posterior Fossa Ependymoma | — | 0.881 |
| 3 | SJEPD001518_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.866 |
| 4 | C3N-00545 | — | cohortA1 | 0.863 |
| 5 | MNG1163 | — | — | 0.861 |
| 6 | SAMN03290921 | — | — | 0.860 |
| 7 | MNG1090 | — | — | 0.857 |
| 8 | BS_W7FP2G3F | DNET | — | 0.847 |
| 9 | R89 | — | — | 0.846 |
| 10 | 7f51ff28-397d-466f-82b0-25e9c9182ea7 | — | — | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| COAGULATION | 0.360 | Binimetinib | — uncovered |
| HYPOXIA | 0.360 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.330 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.310 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.260 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.240 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.220 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.210 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.160 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.160 | Idelalisib | — uncovered |